ANXA1 and inflammatory bowel disease: Indeed, our research group has evidenced AnxA1 is vital for infliximab actions on murine IBD models (de Paula-Silva et al., 2016) and that AnxA1 is a promising biomarker for assessing responsiveness to infliximab in human IBD patients (unpublished observations).